ERRγ, a Novel Biomarker, Associates with Pathoglycemia of Endometrial Cancer to Predict Myometrial Invasion

Table 1

Correlation between expression of ERRγ, myometrial invasion depth, and immunohistochemical markers in EC.

Markers	ERRγ expression n (%)			Myometrial invasion depth n (%)
	Low	High	value	≥1/2	<1/2	value
ER
Negative	0 (0.0)	9 (15.3)	0.102	4 (16.6)	5 (9.1)	0.443
Positive	20 (100.0)	50 (84.7)		20 (83.3)	50 (90.9)
PR
Negative	0 (0.0)	10 (17.2)	0.057	5 (21.7)	5 (9.1)	0.128
Positive	20 (100.0)	48 (82.8)		18 (78.3)	50 (90.9)
Vimentin
Negative	11 (61.1)	13 (23.2)	0.003	3 (12.5)	30 (60.0)	0.018
Positive	7 (38.9)	43 (76.8)		21 (87.5)	20 (40.0)
PTEN
Negative	5 (35.7)	11 (52.4)	0.332	3 (33.3)	13 (50.0)	0.460
Positive	9 (64.3)	10 (47.6)		6 (66.7)	13 (50.0)
P53
Negative	7 (36.8)	27 (45.8)	0.495	9 (37.5)	25 (46.3)	0.470
Positive	12 (63.2)	32 (54.2)		15 (62.5)	29 (53.7)
Ki67
≥50%	12 (60.0)	28 (47.5)	0.332	8 (33.3)	32 (58.2)	0.042
<50%	8 (40.0)	31 (52.5)		16 (66.7)	23 (41.8)

ER: estrogen; PR: progesterone receptor. ; .